Laxmi Organic Industries Limited Q1 FY27 Earnings Call Summary

Event Participants

Executives

2 Amit Jain, Rajan Venkatesh

Analysts

7 Abu Rafa, Giriraj Daga, Hetvi, Manav Mehta, Rohit, Vansh, Vijay

Financials & KPIs

Geographic & Segment Commentary

• Specialty Chemicals: Revenue of ₹241 crore, +17% YoY and +13% QoQ. Q1 saw positive momentum across key specialty products. Dahej expansion will roughly double diketene derivative capability and make Laxmi the global #3 diketene producer; ramp-up is expected through FY28, with focus on FY29.
• Essential Chemicals: Revenue of ₹726 crore, +50% YoY and +39% QoQ, with double-digit volume growth. World-scale ethyl acetate capacity at Lote contributed. Essentials EBITDA was ~11-12% in Q1, though management expects mid-single-digit EBITDA over the cycle.
• Dahej Phase II (Project Vaayu): Mechanical completion and stabilization expected in Q3 FY27, followed by customer qualification in Q3 and ramp-up in Q4. ~85% of Phase II capex will be capitalized in Q2; project is ~60% specialty and ~40% essentials. Revenue contribution is expected from FY28.
• Electrochemical Fluorination: Laxmi remains the first mover/leader in India; management is leveraging it as a technology platform for new specialty products. A robust NPD pipeline is in place, and partnerships will be announced in due course.

Company-Specific & Strategic Commentary

• Macro & Raw Material Volatility: West Asia crisis, Strait of Hormuz/Red Sea disruptions, and the South China typhoon hit logistics and raw-material prices; acetic acid spiked ~200% from a March baseline and methanol spiked even more. Prices moderated late May-June, but Q2 is seeing "West Asia 2.0" and fresh typhoon-related bottlenecks.
• Supply Chain & Procurement Agility: Management secured timely raw-material availability through procurement efficiencies, temporarily increasing net working capital. Priority remains uninterrupted supply and business continuity despite freight and energy cost inflation.
• Competitive Positioning: Management reiterated that upcycles benefit scale players; Laxmi leverages economies of scale and end-to-end integration. Global capacity restructuring in Europe, Japan, and Korea is creating structural opportunities.
• Customer Demand Behavior: Demand was stable across pharma, agro, printing/packaging, with some slowness in pigments and positive momentum in industrial solutions. Customers adopted varied buying stances — just-in-time, just-in-case, and deferment — amid price volatility.
• Project Execution: Dahej remains the key strategic driver; Phase I is capitalized and at good utilization, and Phase II is on track for Q3 mechanical completion. FY27 capex guided at ₹125-150 crore.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Dahej Project – Capitalization and Capex

• Question: Giriraj Daga asked about FY27 Dahej capex and whether the entire ₹600+ crore CWIP plus remaining capex would be capitalized in Q2. (Giriraj Daga)
• Answer: Phase I (~15-18% of total capex) is already capitalized; ~85% of Phase II capex will be capitalized in Q2. FY27 total capex is estimated at ₹125-150 crore. (Rajan Venkatesh)

Dahej Revenue and Return Assumptions

• Question: Giriraj Daga asked about incremental revenue/EBITDA from Dahej in FY28 and whether return assumptions still hold versus project conceptualization.
• Answer: Dahej is 60% specialty and 40% essentials; Phase I is backed by a multi-year MNC contract. Essentials margin assumptions have been impacted, but Q1 essentials EBITDA of ~11-12% shows the cyclical strength. The specialty expansion makes Laxmi the global #3 diketene producer; ramp-up happens in FY28 with focus on FY29. It is too early to judge returns on a quarterly basis. (Rajan Venkatesh)

Margin Sustainability

• Question: Vansh asked whether ~12% margins are sustainable over the medium term.
• Answer: No straight answer; essentials must be viewed over the cycle, as evidenced by the swing from low Q3 FY26 margins to strong Q1 FY27 margins. Scale, integration, and customer relationships underpin the "right to win." Specialty was hit by feedstock deflation and a product phase-out, but FY27 has started positively. (Rajan Venkatesh)

Revenue Growth – Volume/Price Split

• Question: Vansh asked for the volume vs price split in the 40% revenue growth.
• Answer: Volume growth was ~10%; the rest came from price and product mix across multiple products and geographies. (Amit Jain, Rajan Venkatesh)

Essentials Outlook and Acetic Anhydride

• Question: Abu Rafa asked how the essentials business would perform for the rest of FY27 and about acetic anhydride demand from pharma.
• Answer: Essentials requires end-to-end agility across procurement, supply chain, manufacturing, and customer connects; Q1 EBITDA of 11-12% demonstrates the ability to win. Acetic anhydride demand was muted post-COVID but is now showing positive momentum. (Rajan Venkatesh)

Capacity Absorption and Utilization

• Question: Hetvi asked about essentials volume growth and how new capacity will be absorbed to reach optimum utilization.
• Answer: The world-scale ethyl acetate capacity at Lote is commissioned and Dahej Phase I is at good utilization. Laxmi plans to win through economies of scale and cost position, serving markets growing in line or above GDP. Management will provide clearer ramp-up numbers as the year progresses. (Rajan Venkatesh)

Dahej Timeline, ECF, and Base Effects

• Question: Rohit asked about Dahej revenue timeline, electrochemical fluorination customer visibility, Q1 contribution from ECF, and whether the discontinued molecule impacted the base.
• Answer: Mechanical completion is expected early Q3 FY27, with ramp-up alongside the partner and revenue from FY28. Laxmi remains the ECF leader and has a robust specialty NPD pipeline; partnerships will be announced in due course. There was some ECF contribution in Q1, but not full potential due to delayed monsoons. The phased-out molecule had no contribution in Q1 FY26 or during FY26. (Rajan Venkatesh)

Specialty Margin Trajectory

• Question: Manav Mehta asked whether specialty margin pressure is transitional or structurally lower.
• Answer: Two factors hit FY26: a product phase-out (~10% of revenue) and ~25% feedstock deflation. Dahej capacity will allow Laxmi to bring back products it could not produce at Mahad, and raw-material prices are now moving up. Past 20-25% specialty margins may not return in the short term due to new-capacity ramp-up, but Q1 momentum across key products is positive; assess over 2-3 years. (Rajan Venkatesh)

Depreciation and Debt Repayment

• Question: Manav Mehta asked about annualized depreciation post-commissioning and debt reduction.
• Answer: Incremental depreciation will be ~₹7.5 crore per quarter from Q2 FY27. Debt repayment starts next year and will continue for five years. (Amit Jain)

Key Takeaway

Laxmi Organic delivered a strong Q1 FY27, with revenue of ₹968 crore, up 40% YoY and 32% QoQ, and EBITDA of ₹114 crore, up 272% YoY, driven by ~10% volume growth, higher prices, and procurement agility despite acetic acid spiking ~200% from March and disrupted logistics. Essentials generated ₹726 crore revenue (+50% YoY) with EBITDA around 11-12%, while Specialty grew 17% YoY to ₹241 crore with positive momentum. Management is focused on completing Dahej Phase II — mechanical completion and customer qualification in Q3 FY27 and ramp-up in Q4 — with revenue contribution from FY28; FY27 capex is guided at ₹125-150 crore and debt has peaked at ~₹601 crore with 0.3x net debt/equity. Key watchpoints include raw-material volatility, margin cyclicality, working capital normalization, and customer demand caution amid West Asia 2.0 and typhoon-related supply disruptions.